Feasibility of health-related quality of life (HRQoL) assessment for cancer patients using electronic patient-reported outcome (ePRO) in daily clinical practice.


Journal

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
ISSN: 1573-2649
Titre abrégé: Qual Life Res
Pays: Netherlands
ID NLM: 9210257

Informations de publication

Date de publication:
Nov 2021
Historique:
accepted: 23 11 2020
pubmed: 3 1 2021
medline: 26 11 2021
entrez: 2 1 2021
Statut: ppublish

Résumé

Routine Electronic Monitoring of Health-Related Quality of Life (HRQoL) (REMOQOL) in clinical care with real-time feedback to physicians could help to enhance patient-centered care. We evaluated the feasibility of REMOQOL in the French context in the QOLIBRY study. The primary objective was to assess the patients' compliance with REMOQOL. The QOLIBRY study was a single-center, prospective study conducted in the University Hospital of Besançon (France). Eligible patients were those treated with systemic therapies for breast, lung or colorectal cancer at any stage. Patients were invited to complete the EORTC QLQ-C30 questionnaire and cancer-site-specific modules before each visit on tablets and/or computers in the hospital or at home. During the consultation, physicians had real-time access to visual summaries of HRQoL scores. Compliance was assessed as adequate if at least 66% of HRQoL assessments were completed during the 4 months of follow-up. Between March 2016 and October 2018, 177 patients were included in the QOLIBRY study. Median age was 64 years (IQR 54-71). The proportion of patients with an adequate compliance rate was 95.5% (n = 63) in the breast cancer cohort, 98.2% (n = 55) in the colorectal cancer cohort, and 90.9% (n = 50) in the lung cancer cohort. The physicians checked the HRQoL results in 73.1% of visits and prescribed supportive care and adapted patient management in 8.3% and 5.2% of visits, respectively. The results of QOLIBRY study suggest that REMOQOL is feasible in the French context. However, information about HRQoL monitoring, training of the physicians in the use of the software, and recommendations for using HRQoL results to guide care are essential and must be improved.

Identifiants

pubmed: 33387291
doi: 10.1007/s11136-020-02721-0
pii: 10.1007/s11136-020-02721-0
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3255-3266

Subventions

Organisme : Conseil régional de Bourgogne-Franche-Comté
ID : APICHU 2016

Informations de copyright

© 2021. Springer Nature Switzerland AG.

Références

Bottomley, A., Pe, M., Sloan, J., et al. (2016). Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: A start in setting international standards. The Lancet Oncology, 17, e510–e514. https://doi.org/10.1016/S1470-2045(16)30510-1 .
doi: 10.1016/S1470-2045(16)30510-1 pubmed: 27769798
European Medicines Agency European Medicines Agency. (2016). Clinical efficacy and safety—Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man—the use of patient-reported outcome (PRO) measures in oncology studies. Retrieved July 27, 2016 from http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_001127.jsp&mid=WC0b01ac0580034cf3 .
Luckett, T., Butow, P. N., & King, M. T. (2009). Improving patient outcomes through the routine use of patient-reported data in cancer clinics: Future directions. Psychooncology, 18, 1129–1138. https://doi.org/10.1002/pon.1545 .
doi: 10.1002/pon.1545 pubmed: 19319920
Kotronoulas, G., Kearney, N., Maguire, R., et al. (2014). What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials. JCO, 32, 1480–1501. https://doi.org/10.1200/JCO.2013.53.5948 .
doi: 10.1200/JCO.2013.53.5948
Howell, D., Molloy, S., Wilkinson, K., et al. (2015). Patient-reported outcomes in routine cancer clinical practice: A scoping review of use, impact on health outcomes, and implementation factors. The Annals of Oncology, 26, 1846–1858. https://doi.org/10.1093/annonc/mdv181 .
doi: 10.1093/annonc/mdv181 pubmed: 25888610
King, S., Exley, J., Parks, S., et al. (2016). The use and impact of quality of life assessment tools in clinical care settings for cancer patients, with a particular emphasis on brain cancer: Insights from a systematic review and stakeholder consultations. Quality of Life Research, 25, 2245–2256. https://doi.org/10.1007/s11136-016-1278-6 .
doi: 10.1007/s11136-016-1278-6 pubmed: 27039304 pmcid: 4980409
Yang, L. Y., Manhas, D. S., Howard, A. F., & Olson, R. A. (2018). Patient-reported outcome use in oncology: A systematic review of the impact on patient-clinician communication. Supportive Care in Cancer, 26, 41–60. https://doi.org/10.1007/s00520-017-3865-7 .
doi: 10.1007/s00520-017-3865-7 pubmed: 28849277
Anatchkova, M., Donelson, S. M., Skalicky, A. M., et al. (2018). Exploring the implementation of patient-reported outcome measures in cancer care: Need for more real-world evidence results in the peer reviewed literature. The Journal of Patient-Reported Outcomes, 2, 64. https://doi.org/10.1186/s41687-018-0091-0 .
doi: 10.1186/s41687-018-0091-0 pubmed: 30588562
Berry, D. L., Hong, F., Halpenny, B., et al. (2014). Electronic self-report assessment for cancer and self-care support: Results of a multicenter randomized trial. The Journal of Clinical Oncology, 32, 199–205. https://doi.org/10.1200/JCO.2013.48.6662 .
doi: 10.1200/JCO.2013.48.6662 pubmed: 24344222
Chen, J., Ou, L., & Hollis, S. J. (2013). A systematic review of the impact of routine collection of patient reported outcome measures on patients, providers and health organisations in an oncologic setting. BMC Health Services Research, 13, 211. https://doi.org/10.1186/1472-6963-13-211 .
doi: 10.1186/1472-6963-13-211 pubmed: 23758898 pmcid: 3700832
Basch, E., Deal, A. M., Kris, M. G., et al. (2016). Symptom monitoring with patient-reported outcomes during routine cancer treatment: A randomized controlled trial. The Journal of Clinical Oncology, 34, 557–565. https://doi.org/10.1200/JCO.2015.63.0830 .
doi: 10.1200/JCO.2015.63.0830 pubmed: 26644527
Denis, F., Lethrosne, C., Pourel, N., et al. (2017). Randomized trial comparing a web-mediated follow-up with routine surveillance in lung cancer patients. The Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djx029 .
doi: 10.1093/jnci/djx029 pubmed: 28423407
Basch, E., Deal, A. M., Dueck, A. C., et al. (2017). Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA, 318, 197–198. https://doi.org/10.1001/jama.2017.7156 .
doi: 10.1001/jama.2017.7156 pubmed: 28586821 pmcid: 5817466
Denis, F., Basch, E., Septans, A.-L., et al. (2019). Two-year survival comparing web-based symptom monitoring vs routine surveillance following treatment for lung cancer. JAMA, 321, 306–307. https://doi.org/10.1001/jama.2018.18085 .
doi: 10.1001/jama.2018.18085 pubmed: 30667494 pmcid: 6439676
Detmar, S. B., Muller, M. J., Wever, L. D., et al. (2001). The patient-physician relationship. Patient-physician communication during outpatient palliative treatment visits: An observational study. JAMA, 285, 1351–1357.
doi: 10.1001/jama.285.10.1351
Detmar, S. B., Muller, M. J., Schornagel, J. H., et al. (2002). Health-related quality-of-life assessments and patient-physician communication: A randomized controlled trial. JAMA, 288, 3027–3034.
doi: 10.1001/jama.288.23.3027
Velikova, G., Booth, L., Smith, A. B., et al. (2004). Measuring quality of life in routine oncology practice improves communication and patient well-being: A randomized controlled trial. The Journal of Clinical Oncology, 22, 714–724. https://doi.org/10.1200/JCO.2004.06.078 .
doi: 10.1200/JCO.2004.06.078 pubmed: 14966096
Wintner, L. M., Sztankay, M., Aaronson, N., et al. (2016). The use of EORTC measures in daily clinical practice-A synopsis of a newly developed manual. The European Journal of Cancer, 68, 73–81. https://doi.org/10.1016/j.ejca.2016.08.024 .
doi: 10.1016/j.ejca.2016.08.024 pubmed: 27721057
Basch, E., & Snyder, C. (2017). Overcoming barriers to integrating patient-reported outcomes in clinical practice and electronic health records. The Annals of Oncology, 28, 2332–2333. https://doi.org/10.1093/annonc/mdx506 .
doi: 10.1093/annonc/mdx506 pubmed: 28961852
Chan, E. K. H., Edwards, T. C., Haywood, K., et al. (2018). Implementing patient-reported outcome measures in clinical practice: A companion guide to the ISOQOL user’s guide. Quality of Life Research. https://doi.org/10.1007/s11136-018-2048-4 .
doi: 10.1007/s11136-018-2048-4 pubmed: 30448911 pmcid: 8084633
Mouillet, G., Fritzsch, J., Paget-Bailly, S., et al. (2019). Health-related quality of life assessment for patients with advanced or metastatic renal cell carcinoma treated with a tyrosine kinase inhibitor using electronic patient-reported outcomes in daily clinical practice (QUANARIE trial): Study protocol. Health and Quality of Life Outcomes, 17, 1–9. https://doi.org/10.1186/s12955-019-1085-1 .
doi: 10.1186/s12955-019-1085-1
Aaronson, N. K., Ahmedzai, S., Bergman, B., et al. (1993). The European organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in International Clinical Trials in Oncology. JNCI Journal of the National Cancer Institute, 85, 365–376. https://doi.org/10.1093/jnci/85.5.365 .
doi: 10.1093/jnci/85.5.365 pubmed: 8433390
Bergman, B., Aaronson, N. K., Ahmedzai, S., et al. (1994). The EORTC QLQ-LC13: A modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. The European Journal of Cancer, 30A, 635–642.
doi: 10.1016/0959-8049(94)90535-5
Sprangers, M. A., Groenvold, M., Arraras, J. I., et al. (1996). The European Organization for research and treatment of cancer breast cancer-specific quality-of-life questionnaire module: First results from a three-country field study. The Journal of Clinical Oncology, 14, 2756–2768. https://doi.org/10.1200/JCO.1996.14.10.2756 .
doi: 10.1200/JCO.1996.14.10.2756 pubmed: 8874337
Whistance, R. N., Conroy, T., Chie, W., et al. (2009). Clinical and psychometric validation of the EORTC QLQ-CR29 questionnaire module to assess health-related quality of life in patients with colorectal cancer. The European Journal of Cancer, 45, 3017–3026. https://doi.org/10.1016/j.ejca.2009.08.014 .
doi: 10.1016/j.ejca.2009.08.014 pubmed: 19765978
Rabin, R., & de Charro, F. (2001). EQ-5D: A measure of health status from the EuroQol Group. Annals of Medicine, 33, 337–343. https://doi.org/10.3109/07853890109002087 .
doi: 10.3109/07853890109002087 pubmed: 11491192
Holzner, B., Giesinger, J. M., Pinggera, J., et al. (2012). The Computer-based Health Evaluation Software (CHES): A software for electronic patient-reported outcome monitoring. BMC Medical Informatics and Decision Making, 12, 126. https://doi.org/10.1186/1472-6947-12-126 .
doi: 10.1186/1472-6947-12-126 pubmed: 23140270 pmcid: 3529695
Mouillet, G., Fritzsch, J., Thiery-Vuillemin, A., et al. (2019). Physicians’ satisfaction with health-related quality of life (HRQoL) assessment in daily clinical practice using electronic patient-reported outcome (ePRO) for cancer patients. Annals of Oncology, 30, v729–v730. https://doi.org/10.1093/annonc/mdz265.035 .
doi: 10.1093/annonc/mdz265.035
Julious, S. A. (2005). Sample size of 12 per group rule of thumb for a pilot study. Pharmaceutical Statistics, 4, 287–291. https://doi.org/10.1002/pst.185 .
doi: 10.1002/pst.185
Sim, J., & Lewis, M. (2012). The size of a pilot study for a clinical trial should be calculated in relation to considerations of precision and efficiency. The Journal of Clinical Epidemiology, 65, 301–308. https://doi.org/10.1016/j.jclinepi.2011.07.011 .
doi: 10.1016/j.jclinepi.2011.07.011 pubmed: 22169081
Fayers, P. M., Aaronson, N. K., Bjordal, K., et al. (1999). EORTC QLQ-C30 scoring manual. Brussels: Eortc.
R: The R Project for Statistical Computing (2020). Retrieved November 10, 2020 from https://www.r-project.org/index.html .
Schuler, M. K., Trautmann, F., Radloff, M., et al. (2016). Implementation of a mobile inpatient quality of life (QoL) assessment for oncology nursing. Supportive Care in Cancer, 24, 3391–3399. https://doi.org/10.1007/s00520-016-3163-9 .
doi: 10.1007/s00520-016-3163-9 pubmed: 26984243
Bottomley, A., Vachalec, S., Bjordal, K., et al. (2002). The development and utilisation of the European Organisation for research and treatment of cancer quality of life group item bank. The European Journal of Cancer, 38, 1611–1614. https://doi.org/10.1016/s0959-8049(02)00125-9 .
doi: 10.1016/s0959-8049(02)00125-9 pubmed: 12142050
Snyder, C. F., Jensen, R. E., Geller, G., et al. (2010). Relevant content for a patient-reported outcomes questionnaire for use in oncology clinical practice: Putting doctors and patients on the same page. Quality of Life Research, 19, 1045–1055. https://doi.org/10.1007/s11136-010-9655-z .
doi: 10.1007/s11136-010-9655-z pubmed: 20424920
Trautmann, F., Hentschel, L., Hornemann, B., et al. (2016). Electronic real-time assessment of patient-reported outcomes in routine care-first findings and experiences from the implementation in a comprehensive cancer center. Supportive Care in Cancer, 24, 3047–3056. https://doi.org/10.1007/s00520-016-3127-0 .
doi: 10.1007/s00520-016-3127-0 pubmed: 26887586
Duncan, E. A. S., & Murray, J. (2012). The barriers and facilitators to routine outcome measurement by allied health professionals in practice: A systematic review. BMC Health Services Research, 12, 96. https://doi.org/10.1186/1472-6963-12-96 .
doi: 10.1186/1472-6963-12-96 pubmed: 22506982 pmcid: 3358245
Antunes, B., Harding, R., Higginson, I. J., & EUROIMPACT. (2014). Implementing patient-reported outcome measures in palliative care clinical practice: A systematic review of facilitators and barriers. Palliative Medicine, 28, 158–175. https://doi.org/10.1177/0269216313491619 .
doi: 10.1177/0269216313491619 pubmed: 23801463
Mitchell, A. J. (2013). Screening for cancer-related distress: When is implementation successful and when is it unsuccessful? Acta Oncologica, 52, 216–224. https://doi.org/10.3109/0284186X.2012.745949 .
doi: 10.3109/0284186X.2012.745949 pubmed: 23320770
Mejdahl, C. T., Schougaard, L. M. V., Hjollund, N. H., et al. (2020). Patient-reported outcome measures in the interaction between patient and clinician—A multi-perspective qualitative study. The Journal of Patient-Reported Outcomes, 4, 3. https://doi.org/10.1186/s41687-019-0170-x .
doi: 10.1186/s41687-019-0170-x pubmed: 31919602
Velikova, G., Keding, A., Harley, C., et al. (2010). Patients report improvements in continuity of care when quality of life assessments are used routinely in oncology practice: Secondary outcomes of a randomised controlled trial. The European Journal of Cancer, 46, 2381–2388. https://doi.org/10.1016/j.ejca.2010.04.030 .
doi: 10.1016/j.ejca.2010.04.030 pubmed: 20570138
Whittle, A. K., Kalsi, T., Babic-Illman, G., et al. (2017). A comprehensive geriatric assessment screening questionnaire (CGA-GOLD) for older people undergoing treatment for cancer. The European Journal of Cancer Care (Engl). https://doi.org/10.1111/ecc.12509 .
doi: 10.1111/ecc.12509
Giesinger, J. M., Loth, F. L. C., Aaronson, N. K., et al. (2020). Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research. The Journal of Clinical Epidemiology, 118, 1–8. https://doi.org/10.1016/j.jclinepi.2019.10.003 .
doi: 10.1016/j.jclinepi.2019.10.003 pubmed: 31639445

Auteurs

Guillaume Mouillet (G)

Methodological and Quality of Life Unit in Oncology, University Hospital of Besançon, 25000, Besançon, France. gmouillet@chu-besancon.fr.
Department of Medical Oncology, University Hospital of Besançon, Boulevard Fleming, 25000, Besançon, France. gmouillet@chu-besancon.fr.
INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire Et Génique, University Bourgogne Franche-Comté, 25000, Besançon, France. gmouillet@chu-besancon.fr.

Antoine Falcoz (A)

Methodological and Quality of Life Unit in Oncology, University Hospital of Besançon, 25000, Besançon, France.
INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire Et Génique, University Bourgogne Franche-Comté, 25000, Besançon, France.

Joëlle Fritzsch (J)

Methodological and Quality of Life Unit in Oncology, University Hospital of Besançon, 25000, Besançon, France.
INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire Et Génique, University Bourgogne Franche-Comté, 25000, Besançon, France.

Hamadi Almotlak (H)

Department of Medical Oncology, University Hospital of Besançon, Boulevard Fleming, 25000, Besançon, France.

Pascale Jacoulet (P)

Respiratory Medicine Department, University Hospital of Besançon, 25000, Besançon, France.

Xavier Pivot (X)

Institut de Cancérologie Strasbourg Europe, Strasbourg, France.

Cristian Villanueva (C)

Centre de Cancérologie de Grand Montpellier, 34040, Montpellier, France.

Laura Mansi (L)

Department of Medical Oncology, University Hospital of Besançon, Boulevard Fleming, 25000, Besançon, France.
INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire Et Génique, University Bourgogne Franche-Comté, 25000, Besançon, France.

Stefano Kim (S)

Department of Medical Oncology, University Hospital of Besançon, Boulevard Fleming, 25000, Besançon, France.
INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire Et Génique, University Bourgogne Franche-Comté, 25000, Besançon, France.

Elsa Curtit (E)

Department of Medical Oncology, University Hospital of Besançon, Boulevard Fleming, 25000, Besançon, France.
INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire Et Génique, University Bourgogne Franche-Comté, 25000, Besançon, France.

Nathalie Meneveau (N)

Department of Medical Oncology, University Hospital of Besançon, Boulevard Fleming, 25000, Besançon, France.

Olivier Adotevi (O)

Department of Medical Oncology, University Hospital of Besançon, Boulevard Fleming, 25000, Besançon, France.
INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire Et Génique, University Bourgogne Franche-Comté, 25000, Besançon, France.

Marine Jary (M)

Department of Medical Oncology, University Hospital of Besançon, Boulevard Fleming, 25000, Besançon, France.
INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire Et Génique, University Bourgogne Franche-Comté, 25000, Besançon, France.

Guillaume Eberst (G)

INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire Et Génique, University Bourgogne Franche-Comté, 25000, Besançon, France.
Respiratory Medicine Department, University Hospital of Besançon, 25000, Besançon, France.

Angelique Vienot (A)

Department of Medical Oncology, University Hospital of Besançon, Boulevard Fleming, 25000, Besançon, France.
INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire Et Génique, University Bourgogne Franche-Comté, 25000, Besançon, France.

Fabien Calcagno (F)

Department of Medical Oncology, University Hospital of Besançon, Boulevard Fleming, 25000, Besançon, France.

Astrid Pozet (A)

Methodological and Quality of Life Unit in Oncology, University Hospital of Besançon, 25000, Besançon, France.
INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire Et Génique, University Bourgogne Franche-Comté, 25000, Besançon, France.

Oumelkheir Djoumakh (O)

Methodological and Quality of Life Unit in Oncology, University Hospital of Besançon, 25000, Besançon, France.
INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire Et Génique, University Bourgogne Franche-Comté, 25000, Besançon, France.

Christophe Borg (C)

Department of Medical Oncology, University Hospital of Besançon, Boulevard Fleming, 25000, Besançon, France.
INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire Et Génique, University Bourgogne Franche-Comté, 25000, Besançon, France.

Virginie Westeel (V)

Methodological and Quality of Life Unit in Oncology, University Hospital of Besançon, 25000, Besançon, France.
INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire Et Génique, University Bourgogne Franche-Comté, 25000, Besançon, France.
Respiratory Medicine Department, University Hospital of Besançon, 25000, Besançon, France.

Amélie Anota (A)

Methodological and Quality of Life Unit in Oncology, University Hospital of Besançon, 25000, Besançon, France.
INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire Et Génique, University Bourgogne Franche-Comté, 25000, Besançon, France.
French National Platform Quality of Life and Cancer, Besançon, France.

Sophie Paget-Bailly (S)

Methodological and Quality of Life Unit in Oncology, University Hospital of Besançon, 25000, Besançon, France.
INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire Et Génique, University Bourgogne Franche-Comté, 25000, Besançon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH